21 C.F.R. § 314.630
Current through September 30, 2024
Drug products approved under this subpart are subject to the postmarketing recordkeeping and safety reporting requirements applicable to all approved drug products, as provided in §§ 314.80 and 314.81 .
21 C.F.R. §314.630